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Abstract
Cancer subtype information is critically important for designing more effective treatments.
In this thesis, we introduce a new co-clustering algorithm for cancer subtype identification,
which combines the information of gene networks to simultaneously group samples and genes
into biologically meaningful clusters. We call our method network-assisted co-clustering for
the identification of cancer subtypes (NCIS). Prior to clustering, we assign weights to genes:
those that play key roles in the network and/or show significant variations among samples
would be prioritized. This new approach allows us to rely more on genes that are informative
and representative by including the weights as an importance indicator in the clustering
step. Here we introduce a new weighted co-clustering method based on semi-nonnegative
matrix tri-factorization. We evaluated the effectiveness of the algorithm on large-scale
Glioblastoma multiforme (GBM) and breast cancer (BRCA) datasets from TCGA and on
simulated datasets. We found that our NCIS method can achieve more reliable results
with respect to the clinical features compared to conventional semi-nonnegative matrix tri-
factorization methods and consensus clustering. We also train two classifiers for GBM and
BRCA subtypes identification based on NCIS’s results.
This new method will be very useful to comprehensively detect subtypes that are oth-
erwise obscured by cancer heterogeneity, from various types of cancers based on high-
throughput and high-dimensional gene expression data.
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Chapter 1
Introduction
Cancer is a complex disease. All cancers share a common pathogenesis, which is the outcome
of a process of Darwinian evolution occurring among cell populations within the microenvi-
ronments provided by certain tissues. The evolutionary process can promote cells carrying
advantageous genomic alterations that confer the capability to proliferate and survive more
effectively, which may consequently invade tissues to cause cancer and eventually metas-
tasize. However, for different types of cancers, genomes of somatic cells undergo dramatic
but distinct changes during cancer development and progression (Campbell et al., 2010;
Pleasance et al., 2010a,b). Even for the same type of cancer, there are subtypes that harbor
unique sets of changes and exhibit different patterns of gene expression (Perou et al., 2000;
Sorlie et al., 2001; Alizadeh et al., 2000; Bhattacharjee et al., 2001; Golub et al., 1999). The
subtype information is critically important for designing more effective treatments. Recent
advances in next-generation sequencing (NGS) technologies have provided us with an un-
precedented opportunity to study the molecular signatures of human cancers in a much
more refined manner. Several recent large-scale cancer genomic studies have revealed that
the genetic diversity of the same type of cancer (even for the relatively well-characterized
breast cancer (Curtis et al., 2012; Stephens et al., 2012; Banerji et al., 2012; Shah et al.,
2012)) is much greater than previously thought. Therefore, better methods are urgently
needed to discover cancer subtypes based on high-throughput and high-dimensional data.
In the past decade, many clustering-based approaches have been developed to identify
cancer subtypes based on gene expression profiles (Barillot et al., 2012). Typically, expres-
sion levels of d genes measured on n samples are presented as a d × n real-valued matrix,
with rows representing the d genes, columns representing the n samples, and entries for
the corresponding expression level. Then a clustering method is applied to partition the
columns/rows of this matrix into different clusters such that items within one cluster have
more similar expression patterns. The partition of columns offers clues to potential cancer
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subtypes while the partition of rows highlights possible co-expressed genes and pathways
that might be relevant to each subtype. In this work, we mainly focus on the clustering
method for subtype identification. We assume the expression matrix has been pre-processed
such that the batch effects and other technical artifacts are already removed.
The most popular clustering methods used in cancer subtype identification include hier-
archical clustering (Shai et al., 2003; Network, 2012; Bullinger et al., 2004; Phillips et al.,
2006) and k-means (Phillips et al., 2006; Tothill et al., 2008; Lehmann et al., 2011). These
two methods have very intuitive meanings and can capture the nature of the data in many
cases. However, in most of the previous works, biological information (such as gene-gene in-
teractions) was often not incorporated in the clustering step. Sometimes the clustering result
could be very sensitive to measurement error, consequently making subsequent analysis dif-
ficult to perform. On the other hand, gene expression profiles generated by high-throughput
technologies are often of very high dimension, i.e. the number of genes is far larger than the
number of samples, so an appropriate feature (gene) selection method is of vital importance
to successful cancer subtype detection. Utilizing prior knowledge of molecular interactions
could help elucidate more representative genes. For example, upstream genes that regulate
many downstream targets generally have bigger impacts on the overall expression patterns
since their changes can lead to changes of these targets.
Indeed, network is important in understanding cancer (Barabasi et al., 2011; Chuang
et al., 2007). The interactions between genes will allow us to preform clustering by relying
more on modeling the perturbation of a group of related genes rather than individual genes.
Therefore, our goal in this work is to develop a method that effectively incorporates network
information into the clustering process. To this end, a previous work employed information
of biological networks to develop a clustering method (Hanisch et al., 2002). The authors
first defined a network distance based on proximity of two genes in the network and an
expression distance based on expression level similarity of two genes, and then constructed
the overall distance metric as a function of network and expression distance metrics for
hierarchical clustering. There was another work that incorporates network into the cluster-
ing framework proposed to co-cluster genotypes and phenotypes based on phenotype-gene
association matrix (Hwang et al., 2012). The authors did so by adding penalty and regular-
ization terms into co-clustering objective to keep the final clustering results consistent with
clusters obtained from prior knowledge on disease phenotype similarity network and gene
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interaction network. However, similar approaches could be improper for our purpose. First,
network distances (as in (Hanisch et al., 2002)) or network-derived clusters (as in (Hwang
et al., 2012)) are difficult to define for the patients since there is not a network structure
linking all the patients. Second, the rationale that genes are related according to their
proximity in the network may not always be helpful for clustering gene expression profiles
as neighboring genes can have entirely opposite expression patterns: For instance, if Gene
A down-regulates Gene B, their expression levels tend to be anti-correlated, so according to
the commonly used distance metric for heatmap (1-correlation, Euclidian distance, etc.), A
and B will be clustered into two groups, while their positions in the network is very close.
In this work, we integrate network information with expression variation across sam-
ples to train a weight for each gene which is then used as an importance indicator in the
clustering. Such weights will assist us to select genes with greater priority based on the
given dataset and prior knowledge of molecular interactions. The key idea is that genes
regulating many other genes and/or showing highly variable expression patterns should be
considered as more informative in the clustering process. Another important contribution
of this work is that we embed the weights into a “co-clustering” objective function. Un-
like traditional one-sided clustering, co-clustering simultaneously clusters both samples and
features (Tanay et al., 2005). In co-clustering, similarity is a measure of the coherence of
features and samples in bi-cluster (each small block), rather than a function of feature pairs
or sample pairs; consequently, it considers about local context and is able to automatically
select subsets sharing similar attributes (Cheng and Church, 2000). Previous works have
proposed co-clustering methods that are useful in gene expression analysis (Cheng and
Church, 2000; Cho et al., 2004; Ihmels et al., 2002; Ben-Dor et al., 2003; Murali and Kasif,
2003; An et al., 2012; Eren et al., 2012; Li et al., 2009b; Prelic et al., 2006; Hochreiter et al.,
2010; Huttenhower et al., 2009; Gu and Liu, 2008; Lazzeroni and Owen, 2002; Bergmann
et al., 2003). An overview of more co-clustering methods can be found in (Tanay et al.,
2005; Eren et al., 2012; Prelic et al., 2006; Madeira and Oliveira, 2004). The method we
use here is based on Semi-Nonnegative Matrix Tri-Factorization (SNMTF) (Ding et al.,
2006; Gu and Zhou, 2009), which is a member of the matrix factorization based cluster-
ing family. A common underlying motivation of this family of co-clustering methods is
that there exist some cluster centroids that can characterize the behaviors and trends of
their cluster members, so the goal is to minimize the overall distances to cluster centroids,
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which mathematically is formed into matrix tri-factorization. Matrix factorization has sim-
ple formalization, as compared to other methods, and was shown to be very useful in gene
expression analysis (Barillot et al., 2012; Kim and Park, 2007; Brunet et al., 2004; Gao and
Church, 2005; Li et al., 2009a; Qi et al., 2009) and also in network reconstruction (Yang
et al., 2009; Kim et al., 2011) as well as regulatory module detection (Zhang et al., 2011).
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Chapter 2
Methods
2.1 Method Overview
We propose a clustering method that incorporates gene network (i.e. the interactions be-
tween genes) as prior knowledge and simultaneously cluster samples and genes into distinct
groups. Adding network structure to the clustering step itself will help us better select
representative genes for clustering and thus generate biologically informative clusters. The
method can more effectively identify clusters that are otherwise obscured by a large number
of genes. The main scheme of our method is shown in Figure 1. We first use network struc-
ture and expression variation to train a weight for each gene. We then perform a weighted
co-clustering to identify gene sets that can cluster the samples into subtypes.
Figure 1: Schematic diagram of NCIS.
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2.2 Assigning Weights to Genes
High-dimensionality is a common feature of most gene expression profiles obtained nowadays
using high-throughput technologies (such as microarray or RNA sequencing). Hence feature
selection is vital to successfully detect patterns from the data. In many previous works, genes
were selected based on their median absolute deviation (MAD) or coefficient of variation
(CV) (Verhaak et al., 2010; Liu et al., 2008). A cutoff was set and typically only a very
small subset of genes was retained for subsequent analysis. This approach depends on an
arbitrary threshold and much of the information might be lost due to drastically reducing the
number of genes at the very beginning. Other classical dimension-reduction methods such
as principal component analysis (PCA) (Alter et al., 2000) are helpful, but the biological
interpretations are not always easy as expression vectors of the samples are projected to a
low-dimensional principal component space (Barillot et al., 2012; Jiang et al., 2004). On the
other hand, incorporating additional biologically relevant information as prior knowledge
could help resolve ambiguities of the data since it provides, to a certain extent, insights
about the mechanisms of how the data was generated. Therefore, we utilize network as well
as expression information to select genes that play important roles and/or show significant
variations among samples. We do so by assigning a weight to each gene – important genes
receive higher weights and will be considered more in the weighted co-clustering.
We employ a modified PageRank algorithm here. PageRank has been successfully used
as the basis of Google search engine (Page et al., 1999; Brin and Page, 1998). The algorithm
views the web as a directed graph. Suppose there are N nodes (web pages), then adjacency
matrix E is a N × N matrix denoting the connectivity between the nodes. A link from
page i to page j is illustrated by an edge pointing from node i to node j, and in the matrix
form denoted by Eij = 1. More links to node n raises its confidence level. Therefore, the
algorithm ranks all the nodes based on the iterative formula:
rnj = (1− α) + α
N∑
i=1
Eijr
n−1
i
degi
, 1 ≤ j ≤ N, (2.1)
where rn is the rank in the nth iteration and degi =
∑N
j=1Eij , meaning the total number
of hyperlinks in web page i; α is a tuning parameter representing the extent to which the
ranking depends on the structure of the graph.
In our case, we have a similar network structure representing the molecular interactions
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between genes. Our method that assigns weights to genes is largely inherited from a gene
ranking method named GeneRank (Morrison et al., 2005). The authors extended the idea
of PageRank to microarray gene differential expression analysis, where genes were ranked
according to their connections to other genes and their differential expression. However,
we use a directed graph here (rather than the undirected graph in GeneRank), because we
believe a gene which regulates (rather than regulated by) many important genes should
receive larger weights. In other words, the directionality is important. We also have a
different way incorporating the gene expression since we often do not have a differential
expression measure without knowing the subtypes.
In our graph, a directed edge from node i to node j means that gene i regulates the ex-
pression of gene j. Besides, generally genes with larger variations among samples have larger
distinguishing power, so we incorporate such variation into the model to assign weights. Our
main idea is that genes having a lot of heavy weighted down-stream targets should be as-
signed a large weight – a rationale similar to the confidence vote in the original web page
ranking problem. For example, if gene A regulates gene B and gene C, and if B and C
are highly variable among the patients or regulates other highly variable genes, then we
should increase the weight of A in addition to its own variation level. Another important
point to mention is that if B and C are also regulated by many other genes, the influence
of A in determining the behaviors of B and C should be less, and so the increase of A’s
weight should be less accordingly. Taken together, we propose the following weight-training
algorithm:
wnj = (1− α)NMADj + α
N∑
i=1
Ejiw
n−1
i
degi
, 1 ≤ j ≤ N, (2.2)
where wn is the weight vector of genes in the nth iteration and NMAD is the normalized
median absolute deviation (MAD) defined as:
NMADi =
MADi
‖MAD‖ , (2.3)
where ‖MAD‖ is the L1 norm of vector MAD.
We use MAD as a measurement of the expression variation of a gene among all the
samples. The values are normalized by the sum of all MADs to make the weight-training
mechanism stable and comparable with different overall expression levels. In each iteration,
every gene is evaluated by its own MAD as well as the weights and connectivity of the
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genes it regulates. Therefore, the final weight of each gene can reflect both its impact in
the network structure and its ability to separate the samples.
The convergence of this iterative algorithm is guaranteed for any 0 < α < 1 (Morrison
et al., 2005; Higham and Taylor, 2003). Let wn+1 = wn, we have
wnj = (1− α)NMADj + α
N∑
i=1
Ejiw
n
i
degi
, 1 ≤ j ≤ N, (2.4)
in the matrix form is
wn = (1− α)NMAD + αED−1wn, (2.5)
where D is a diagonal matrix with entries degi, 1 ≤ j ≤ N .
Therefore, the final weight for all the genes can be represented as:
w = (1− α)× (I − αED−1)−1 ×NMAD, (2.6)
where I is the N ×N identity matrix.
To make weights trained with different parameters more comparable, we normalized w
such that ‖w‖ = 1. We chose a relatively large α value to make the weights rely more on the
network structure. It is worth noting that if α = 0 the weight of a gene would be proportional
to its MAD – depending purely on expression variation. In this case, network information
is not used to assist the clustering, so our method would be the same with variation-based
feature selection except that we use a softer “filter”. To illustrate the influence of α and to
make a comparison, we also evaluated the co-clustering results without using the network
information in the Results section.
2.3 Weighted Co-clustering
After assigning weights to genes, our input data includes the gene expression profile of each
sample and the weights for all the genes based on the network information. We propose
a weighted co-clustering method to simultaneously group samples into subtypes and group
genes into functionally relevant subclasses. Our method is based on Semi-Nonnegative
Matrix Tri-Factorization (SNMTF), where the nonnegative constraint on the data matrix
imposed in Orthogonal Nonnegative Matrix Tri-Factorization (ONMTF) is relaxed to make
it suitable for general datasets (Ding et al., 2006; Gu and Zhou, 2009). Nonnegative
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Matrix Factorization (NMF)-based clustering methods have been shown useful for many
applications, such as text mining (Xu et al., 2003) and gene expression analysis (Kim and
Park, 2007). We chose SNMTF also because of its simplicity and intuitive interpretation:
it can be viewed as a two-way k-means in terms of minimizing the distances to cluster
centroids. This will be discussed in detail in the optimization part. A method similar to
SNMTF was proposed and the author called it double k-means (Vichi, 2001).
2.3.1 Objective
Suppose our gene expression matrix X contains d genes and n samples, and we would like
to group the genes into m clusters and group the samples into c clusters (cancer subtypes).
For convenience, the main notations used in the rest of the thesis are presented in Table 1.
Table 1: Main notations
Notation Description
n Number of samples
d Number of genes
c Number of sample clusters
m Number of gene clusters
X Gene expression matrix of size d× n
X·i The ith column of X, representing the expression of the ith sample
Xi· The ith row of X, representing the expression of the ith gene
F
Sample partition matrix of size n× c; Fij ∈ [0, 1] : Fij = 1 if X·i
belongs to sample cluster j and Fij = 0 otherwise
G
Feature partition matrix of size d ×m; Gij ∈ [0, 1] : Gij = 1 if
Xi· belongs to gene cluster j and Gij = 0 otherwise
S A m× c matrix
W A d× d diagonal matrix; entries are the weights of the genes
Our method can be specified as minimizing the following objective,
‖X −GSFT ‖2W =
d∑
i=1
‖Xi· − (GSFT )i·‖2 ×Wii
= tr(XTWX − 2XTWGSFT + FSTGTWGSFT ).
(2.7)
Here G denotes the cluster each gene belongs to and F denotes the cluster of each
sample. The matrix S can be treated as centroids of the bi-clusters (blocks in heatmap)
generated. Weights trained before are presented in the diagonal matrix W , and we incor-
porate this importance indicator by multiplying the weights to the squared row (genes)
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norms. Therefore, in the optimization step, genes with larger weights contribute more and
have higher priority. If W = I, i.e. all the genes have same weight 1 and are treated equally,
it degenerates to the ordinary co-clustering method. Due to difficulties in minimizing the
objective with the binary-value constraint on F and G, we relax F and G into continuous
nonnegative domain as in previous related work (Gu and Zhou, 2009). We only require∑m
j=1Gij = 1,
∑c
j=1 Fij = 1. Thus our objective is to minimize:
J = tr(XTWX − 2XTWGSFT + FSTGTWGSFT ),
s.t.G ≥ 0 , F ≥ 0,
m∑
j=1
Gij = 1,
c∑
j=1
Fij = 1.
(2.8)
2.3.2 Optimization
We set:
∂J
∂S
= 0. (2.9)
Then we have:
S = (GTWG)−1GTWXF (FTF )−1. (2.10)
We can get a clearer understanding of S from this expression. If G and F are defined as
in Table 1, i.e., 0/1-valued partition matrix, FTF should be a c× c diagonal matrix, whose
entries represent the number of samples belonging to each sample cluster, andGTWG should
be am×m diagonal matrix, with entries equal to the total weights of features (genes) belong-
ing to each of the m feature (gene) clusters; similarly to the interpretation of FTF , GTWG
can be considered as the weighted total number of features in each feature cluster (taking
feature i as wi features when counting the total number). Therefore, (G
TWG)−1GTWX
represents the feature cluster centroids on the sample space (n-dimension) and XF (FTF )−1
represents the sample cluster centroids on the feature space (d-dimension). The difference
is that all the samples are assumed to have same weights equal to 1 while feature points
are assigned different weights W . S then can be viewed as feature cluster centroids on the
sample-centroids space (c-dimension) or as sample cluster centroids on the gene-centroids
space (m-dimension). Therefore, it gives the centroids information of the bi-clusters (m×c)
after partitioning.
Now, assume S and G are fixed. Let β ∈ Rn×c be the Lagrangian multiplier for F , then
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Lagrangian function for F is
L(F ) = J − tr(βFT ). (2.11)
We set:
∂L(F )
∂F
= 0. (2.12)
Using Karush-Kuhn-Tucker condition (Boyd and Vandenberghe, 2004), we have
(−A+ +A− + FB+ − FB−)ijFij = 0, (2.13)
where A = XTWGS, B = STGTWGS; M+ and M− are the positive and negative of
matrix M defined as M+ = |M |+M2 ,M
− = |M |−M2 , respectively. Therefore, we obtain the
iterating formula for F :
Fij ← Fij
√
(A+ + FB−)ij
(A− + FB+)ij
. (2.14)
Similar derivation leads to the iterative formula of G:
Gij ← Gij
√
(C+ +WGD−)ij
(C− +WGD+)ij
, (2.15)
where C = WXFST , D = SFTFST .
The iterations decrease the value of the objective function, J . We include the proof of
convergence of this algorithm in the following section.
Therefore, our algorithm is as follows:
• Initialize F and G.
• While not convergent and iterations less than a pre-defined value
– Update S by
S = (GTWG)−1GTWXF (FTF )−1;
– Update F by
Fij ← Fij
√
(A+ + FB−)ij
(A− + FB+)ij
;
– Update G by
Gij ← Gij
√
(C+ +WGD−)ij
(C− +WGD+)ij
.
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2.3.3 Proof of convergence
We use the auxiliary function approach to prove the convergence of our algorithm.
Z(h, h′) is called an auxiliary function for F (h) if Z(h, h′) ≥ F (h) and Z(h, h) = F (h).
Let h(t+1) = arg minh Z(h, h
(t)), then F (h(t+1)) ≤ Z(h(t+1), h(t)) ≤ Z(h(t), h(t)) ≤ F (h(t)).
Lemma 1. For any matrices U ∈ Rk×k+ , M, M ′ ∈ Rn×k+ , if U is symmetric, the following
inequality holds:
n∑
i=1
k∑
j=1
(M ′U)ijM2ij
M ′ij
≥ tr(MTMU). (2.16)
Proof. Let Mij = vijM
′
ij .
LHS =
n∑
i=1
k∑
j,l=1
M ′ilUljM
′
ijv
2
ij =
n∑
i=1
k∑
j,l=1
M ′ilUljM
′
ij
v2ij + v
2
il
2
.
RHS =
n∑
i=1
k∑
j,l=1
vilM
′
ilvijM
′
ijUjl =
n∑
i=1
k∑
j,l=1
M ′ilUljM
′
ijvijvil.
Therefore,
LHS −RHS =
n∑
i=1
k∑
j,l=1
M ′ilUljM
′
ij
(vij − vil)2
2
≥ 0.
For any real-valued matrix A, define A+ = |A|+A2 , A
− = |A|−A2 .
Theorem 1. Let J(M) = tr(−2PMT +MQMT ), where P ∈ Rn×k and Q ∈ Rk×k are fixed
matrices, and Q is symmetric, M ∈ Rn×n. Then
Z(M,M ′) = −2
∑
i,j
P+ijM
′
ij(1 + log
Mij
M ′ij
) +
∑
i,j
P−ij
M2ij +M
′
ij
2
2M ′ij
+
∑
i,j
(M ′Q+)ijM2ij
M ′ij
−
∑
i,j,l
Q−jlM
′
ijM
′
il(1 + log
MijMil
M ′ijM
′
il
)
(2.17)
is an auxiliary function of J(M).
Furthermore, fixing M ′, Z(M,M’) is a convex function of M and it has the global mini-
mum at
Mij = M
′
ij
√√√√P+ij + (M ′Q−)ij
P−ij + (M ′Q+)ij
(2.18)
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Proof.
∀x ∈ R+, 1 + log x ≤ x
=⇒ P+ijM ′ij(1 + log
Mij
M ′ij
) ≤ P+ijMij ; Q−jlM ′ijM ′il(1 + log
MijMil
M ′ijM
′
il
) ≤ Q−jlMijMil
a2 + b2 ≥ 2ab =⇒ P−ij
M2ij +M
′
ij
2
2Mij
≥ P−ijMij .
Lemma1 =⇒ (M
′Q+)ijM2ij
M ′ij
≥ tr(MTMQ+).
Therefore,
Z(M,M ′) ≥ −2tr(P+MT ) + 2tr(P−MT ) + tr(MTMQ+)− tr(MQ−MT ) = J(M).
To find the minimum of Z(M,M ′), we take
∂Z
∂Mij
= −2P+ij
M ′ij
Mij
+ 2P−ij
Mij
M ′ij
+ 2
(M ′Q+)ijMij
M ′ij
− 2(M
′Q−)ijM ′ij
Mij
,
∂2Z
∂Mij∂Mlm
= δilδjm(2P
+
ij
M ′ij
M2ij
+ 2
P−ij
M ′ij
+ 2
(M ′Q+)ij
M ′ij
+ 2
(M ′Q−)ijM ′ij
M2ij
) ≥ 0.
Therefore, Z(M,M ′) is a convex function of M .
Let ∂Z∂Mij = 0, we have Mij = M
′
ij
√
P+ij+(M
′Q−)ij
P−ij+(M ′Q+)ij
.
Therefore, arg minM Z(M,M
′) has entries M ′ij
√
P+ij+(M
′Q−)ij
P−ij+(M ′Q+)ij
.
Let P = XTWGS = A, Q = STGTWGS = B and M = F , we can see that updating
F using
Fij = Fij
√√√√A+ij + (FB−)ij
A−ij + (FB+)ij
(2.19)
monotonically decreases the value of the objective function J in the method part. Besides,
we know that J ≥ 0, so the updating algorithm converges. Since W is a diagonal matrix
with positive entries, we can similarly let P = XFST = W−1C, Q = SFTFST = D and
M = G, so updating G using
Gij = Gij
√√√√C+ij + (WGD−)ij
C−ij + (WGD+)ij
= Gij
√√√√ (W−1C)+ij + (GD−)ij
(W−1C)−ij + (GD+)ij
(2.20)
monotonically decreases the value of the objective function J , and as J ≥ 0, the updating
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algorithm converges.
2.3.4 m and c selection
A question raised in almost all clustering methods is how to determine the cluster numbers.
There is no agreed-upon solution. Here we utilize an approach taking advantage of the
stochastic property of the algorithm: NCIS may not converge to the same solution on
each run with different initiation; however, if the clustering is strong enough, we would
expect that the results of multiple runs would be very stable (Brunet et al., 2004; Monti
et al., 2003). As in (Brunet et al., 2004; Monti et al., 2003), we run NCIS for 50 times with
randomly-set initiations and get a sample consensus matrix Ms and a gene consensus matrix
Mg. For each run, a n × n sample connectivity matrix Ms and a d × d gene connectivity
matrix Mg are obtained.
Ms(i, j) =
 1 if Sample i and Sample j belong to the same cluster0 otherwise (2.21)
Mg(i, j) =
 1 if Gene i and Gene j belong to the same cluster0 otherwise (2.22)
Consensus matrices Ms and Mg are the averages of Ms’s and Mg’s over the 50 runs
respectively. The entries would range between 0 and 1, where 0 indicates that the corre-
sponding samples (genes) belong to different clusters in every run and 1 indicates that they
belong to the same clusters in all the cases. Therefore, 1−M offers a new distance metric
evaluating the similarity of the items (1−Ms for samples and 1−Mg for genes). Similar to
(Brunet et al., 2004), we use 1−Ms and 1−Mg to hierarchically cluster samples and genes,
and then we define an average cophenetic correlation coefficient
ρ(Ms)+ρ(Mg)
2 to evaluate
the stability over 50 runs. Cophenetic correlation coefficient ρ of matrix C is defined as
the Pearson correlation between distance matrix 1 − C and the distance matrix induced
by the linkage used in hierarchical clustering for re-ordering C. If a clustering is stable,
the entries would be close to 0 and 1 (two modes), and in the ideal case (only 0 and 1)
the average cophenetic correlation coefficient would be exactly 1. So we observe how the
cophenetic correlation coefficients change as m and c change, and select point where the
averaged coefficient begins to fall.
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Chapter 3
Results
We applied NCIS to two large-scale datasets from TCGA. We also used simulated datasets
to evaluate the effectiveness of our method. The network was built using a variety of
sources, including the network used in (Ciriello et al., 2012) as well as our up-to-date
curated information from Reactome (Croft et al., 2011), the NCI-Nature Curated PID
(Schaefer et al., 2009), and KEGG (Kanehisa et al., 2012). The resulting aggregated
network consisted of 11,648 genes and 211,794 edges. For some gene pairs, we can just
tell a connection between them but not able to identify the direction of the regulation, so
we assign two links with opposite directions between them. We allow users to input other
network information in the MATLAB implementation of our method.
3.1 Breast Cancer Dataset
The first dataset we used is from a recent large-scale breast cancer study done by TCGA
(Network, 2012). This dataset contains the expression of 17,814 genes across 547 samples.
We first integrated the gene expression profile with the network information, and trained
weights for 8,726 genes included in both resources. In this step, we set α = 0.85. The 8,726
weighted genes and 547 samples were the input of the co-clustering algorithm. Figure 2
shows the heatmap with genes and samples rearranged according to the clustering result.
Based on the cophenetic correlation coefficient calculated from 50 runs (see Method part),
we chose c = 5 and m = 8 (data shown in Table 2).
Since we do not know the true class each sample belongs to or even how many subtypes
there are, we used clinical features to evaluate the effectiveness of the clustering algorithm.
The underlying idea is that patients in different subgroups are expected to have distinct
clinical characteristics. In addition, as the goal of cancer subtype detection is to assist diag-
nostic of the disease and designing more specific and targeted treatment, a good clustering
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Table 2: Cophenetic coefficients for BRCA data
m = 6 m = 7 m = 8 m = 9
c = 4 0.931 0.925 0.930 0.944
c = 5 0.930 0.940 0.948 0.942
c = 6 0.924 0.929 0.945 0.947
c = 7 0.926 0.928 0.942 0.937
c for number of subtypes, m for number of
gene clusters.
result need to reflect certain clinical information.
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Figure 2: Heatmap of breast cancer expression data. Samples and genes rearranged
according to our NCIS results. Genes listed are the 35 genes used to train classifier. Genes
with “*” are those previously reported to be associated with breast cancer.
We used the following clinical information to evaluate subtypes identification result: sur-
vival time, age at initial pathologic diagnosis, AJCC staging information (neoplasm disease
lymph node stage, neoplasm disease stage and tumor stage) and tumor nuclei percentage.
Table 3 gives the significance level of the difference among all subtypes for each feature.
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Given p-value threshold 0.05, we can conclude that the NCIS-defined subtypes successfully
separated the patients according to all of these clinical features.
Table 3: P-value of the dependence test for different clinical features and BRCA
subtypes
Method Survival Age
Neoplasm
disease
lymph node
stage
Neoplasm
disease
stage
Tumor
stage
Tumor
nuclei
percent-
age
NCIS 0.0444**
1.01 ×
10−3*** 2.03× 10
−3*** 1.68 ×
10−3***
2.33 ×
10−3***
6.17 ×
10−3***
NCIS
(α = 0)
0.0442**
1.96 ×
10−3*** 6.22× 10
−3*** 3.84 ×
10−3***
2.67 ×
10−3***
6.24 ×
10−3***
NCIS
(W = I)
0.195
9.20 ×
10−4*** 9.95× 10
−4*** 2.11 ×
10−3***
4.85 ×
10−3***
4.67 ×
10−3***
Consensus
clustering
(k = 3)
0.497
2.04 ×
10−3*** 0.123 0.266 0.175
5.90 ×
10−3***
Consensus
clustering
(k = 5)
0.359
3.40 ×
10−3*** 3.29× 10
−3*** 2.08 ×
10−4*** 0.187
8.35 ×
10−3***
BRCA
paper
(Network,
2012)
0.831
3.23 ×
10−6*** 0.396 0.337 0.999 0.0780*
For survival time, we used logrank test; for AJCC neoplasm disease lymph node stage,
AJCC neoplasm disease stage and AJCC tumor stage, we used Chi-squared test; for
tumor nuclei percentage and age at initial pathologic diagnosis, we used ANOVA. In all
the 547 samples, there are 22 tumor-adjacent normal tissue samples. They were assigned
to same subtypes by all the clustering methods we used. We ignored these “normal”
subtypes in the clinical feature tests, as these subtypes contain few samples after the 22
normal ones were excluded. * for p < 0.1, ** for p < 0.05, *** for p < 0.01.
We also set α = 0 in the co-clustering method, i.e. no network information was used, to
see the impact of network structure in the clustering results. Similar statistical tests were
performed and the results were presented in Table 3. Comparing the p-values under the two
methods, we did observe an improvement with network information added, in separation of
all the clinical features.
In the original paper (Network, 2012), the authors performed a hierarchical clustering
using a subset of genes (most varied across samples) and identified 13 subtypes (test results
for clinical features are shown in Table 3 as BRCA paper). Since consensus hierarchical
clustering generally performs better than the traditional hierarchical clustering, we applied
a consensus average linkage hierarchical clustering (Monti et al., 2003; Wilkerson and Hayes,
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2010) to cluster the samples. To make a fair comparison, we used all the 8,726 genes. The
program was run over 1,000 iterations and the resampling rate of the sample was set to
be 0.8. The distance metric is 1 minus Pearson’s correlation coefficient. The algorithm
suggested 3 subtypes be identified. However, in Table 3, we listed the tests p-values of
both 3-subtypes and 5-subtypes conditions to make it easier to compare with the results
of NCIS. The results indicated that in the perspective of all these clinical characteristics
except for AJCC neoplasm disease stage, clusters generated by consensus clustering are
not as informative as those of NCIS. We think the most important reason for the poorer
performance of consensus clustering is a lack of effective feature selection method. Consensus
clustering is well designed itself, however, when there are a large number of genes included in
the expression profile, the users must first filter out non-informative ones before performing
the clustering, otherwise the true signals will be weakened by strong noises.
The major advantages of NCIS is the incorporation of the network structure and as-
signing an importance indicator to each gene, so besides generating the co-clusters, we also
obtained a bi-product – the gene weights, which describe the genes’ roles in the network and
abilities to distinguish the patients. After getting the subtypes, we trained a classifier so
that when a new patient is diagnosed, we can easily predict his/her subtype based on the ex-
pression levels of a few signature genes. We first selecting out 35 genes (shown in Figure 2):
we performed ANOVA tests for each gene’s expression levels across the five subtypes, and
then chose the first 35 genes with largest weights and smallest p-values. We constructed
a classifier based on SVM with these 35 genes. In order to test the performance of this
classifier, we performed 10-fold cross validation on this BRCA dataset for 20 times. In this
step, we also tried to use other numbers of genes as classification features. We collected the
average 10-fold cross validation accuracy (20 times) for each case. We chose 35 because it is
the smallest number that can give an accuracy larger than 0.90 (Figure 3). After evaluating
the accuracy with 10-fold cross validation, we trained a classifier using all the 547 samples
(35 genes). We used this classifier to predict the subtypes of these 547 sample in turn. The
accuracy is 0.978.
We tested the functions of these 35 genes. They are enriched in pathways related to cell
cycle, cell division, etc. (Table 4, from DAVID (Huang da et al., 2009a,b)). According to
GeneCards (www.genecards.org) (Safran et al., 2010), all these genes are highly associated
with breast cancer based on previous publications, except for CDCA8, ABCC8, CDC45L,
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Figure 3: Accuracies of BRCA subtype classifiers trained with different numbers
of genes. Genes with largest weights and largest expression differences were used.
IL12RB2 and LRP8. However, CDCA8 encodes a protein relevant to mitosis and cell
division regulation; ABCC8 is involved in multi-drug resistance; CDC45L is required for
initiation of chromosomal DNA replication; IL12RB2 is related to immune response; LRP8
is the cell receptor of Reelin and Reelin has been reported to be important in controlling
invasiveness and metastatic potential of breast cancer cells (Stein et al., 2010). Therefore,
these five genes might also play a role in breast cancer.
We extracted the subnetwork of ABCC8 as an example to illustrate the differences of
the five subtypes in network level (Figure 4). There are 9 genes targeted by ABCC8 in the
network we used. We chose this subnetwork because it has a small size and is easy to be
presented clearly. As can be seen from Figure 4, ABCC8 is highly expressed in Subtypes
Luminal A and Luminal B. Its downstream gene KCNJ11 has very similar expression pattern
with it: KCNJ11 is also highly expressed in Luminal A and Luminal B, but has very low
expression levels in the other three subtypes where ABCC8 is less expressed. There are
many other such examples, which further confirm the differential expression pattern between
subtypes in network level – a main assumption of our method.
As PAM50 (Parker et al., 2009) is widely used in breast cancer subtype detection, we
compared the results of our classifier with that from PAM50 (Network, 2012; Parker et al.,
2009). For these 547 samples, 372 of them (68%) have same subtypes predicted by both
PAM50 and our classifier (p-value for chi-squared test  10−10 (Network, 2012)). This
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Table 4: Pathways enriched by BRCA 35 genes
Term P-value
Cell cycle 5.45× 10−19
Oocyte meiosis 5.05× 10−15
Pathways in cancer 1.23× 10−14
Prostate cancer 3.40× 10−11
p53 signaling pathway 1.11× 10−9
Progesterone-mediated oocyte maturation 3.59× 10−9
Cytokine-cytokine receptor interaction 7.59× 10−7
Glioma 1.15× 10−5
Melanoma 1.75× 10−5
Pancreatic cancer 1.90× 10−5
Small cell lung cancer 2.71× 10−5
Colorectal cancer 3.02× 10−5
Focal adhesion 3.55× 10−4
Non-small cell lung cancer 6.43× 10−4
Chronic myeloid leukemia 1.30× 10−3
Endocytosis 5.12× 10−3
ABC transporters 0.0163
Bladder cancer 0.0290
p-value<0.05, results from DAVID.
concordance further supports that our method provides a pipeline which can be very useful
in cancer subtype prediction. By comparing the genes used in the two classifiers, we found
there are 7 genes overlapped. Although the remaining genes are different, their functions
are similar. According to DAVID (Huang da et al., 2009a,b), PAM50’s 50 genes are also
enriched in pathways related to cell cycle, cell division, etc. (Table 5).
Though the results of NCIS-derived classifier and PAM50 were highly consistent globally,
we further investigated samples that were assigned different class labels by the two methods.
We focused on the expression values of 100 top-ranked genes as these genes were considered
most important in our clustering method. We got the median expression levels of these
genes for each subtype using the samples that were categorized into this specific subtype by
both methods (this subtype information we think should be reliable), and then compared
expression levels of samples that were predicted to different subtypes with these median
values. In this comparison, only 53 samples (30.1%) have expression profiles more similar
to PAM50-predicted subtypes.
In summary, we conclude that NCIS can detect breast cancer subtypes very reliably.
Besides, it also provides an effective approach to train a classifier that can be used for
dialogistic purpose.
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Figure 4: Expression patterns of ABCC8 subnetwork in BRCA subtypes. Genes
directly connected to ABCC8 and genes targeting ABCC8’s downstream genes are included.
Color of circle corresponds to gene expression level; size of circle corresponds to gene weight.
a. Subtype Luminal A; b. Subtype Basal; c. Subtype Luminal B; d. Subtype HER2-
enriched; e. Subtype Normal-like.
3.2 Glioblastoma Dataset
The second dataset we used is from a large-scale Glioblastoma multiforme (GBM) subtype
identification work (Verhaak et al., 2010). The authors integrated data generated on three
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Table 5: Pathways enriched by PAM50 50 genes
Term P-value
Cell cycle 8.10× 10−7
Prostate cancer 6.02× 10−4
Bladder cancer 8.27× 10−4
Oocyte meiosis 1.34× 10−3
Pathways in cancer 2.72× 10−3
p53 signaling pathway 3.35× 10−3
Colorectal cancer 6.07× 10−3
Endometrial cancer 0.0226
p-value<0.05, results from DAVID.
platforms into a single dataset using factor analysis. This unified dataset contains the
expression of 11,861 genes on 200 GBM and 2 normal brain samples. In the original paper,
the authors first selected 1,903 variably expressed genes according to the MAD and then
applied consensus hierarchical clustering with agglomerative average linkage (Monti et al.,
2003). Four subtypes were detected.
We integrated the gene expression information with the network information to train
a weight for each of the 7,183 genes included in both sets. Tuning parameter α in the
algorithm was set to be 0.85. After obtaining the weights, these 7,183 weighted-genes and
the 202 samples were used in the co-clustering. We set m = 7 and c = 4. The cluster
numbers were chosen in the way described in the method section (Table 6).
Table 6: Cophenetic coefficients for GBM data
m = 6 m = 7 m = 8 m = 9
c = 4 0.911 0.920 0.904 0.916
c = 5 0.903 0.904 0.906 0.899
c = 6 0.902 0.892 0.902 0.894
c for number of subtypes, m for number of
gene clusters.
Since we do not have a “gold standard” for the clustering results here either, we used
clinical characteristics to evaluate the effectiveness of our method again. From all the clinical
features provided in this dataset, we used survival time, age at first diagnosis, tumor necrosis
percentage, and tumor nuclei percentage.
Table 7 gives the significance level of the difference among all subtypes for each feature.
Given a p-value threshold 0.05, NCIS results separated the samples in their survival time,
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Figure 5: Heatmap of GBM expression data. Rearranged according to our NCIS
results. Genes listed are the 30 genes used to train classifier. Genes with “*” are those
previously reported to be associated with glioblastoma.
tumor necrosis percentages and tumor nuclei percentages very well. Besides, the ages at
first diagnosis also showed difference to a certain extent. Therefore, we think NCIS performs
well on this dataset in detecting clinically distinct GBM subtypes. Interestingly, we also
observed that Subtype Pronueral has a much higher survival rate than the other three
subtypes (Figure 6). The underlying mechanism for this significant difference deserves more
study.
We also used consensus average linkage hierarchical clustering (Monti et al., 2003;
Wilkerson and Hayes, 2010), as the author did in the paper, but on the 7,183-gene dataset,
to cluster the samples. The program was run over 1,000 iterations and the resampling
rate of the sample was set to be 0.8. The distance metric is 1 minus Pearson’s correlation
coefficient. We identified 4 clusters among the patients. According to the p-values, NCIS-
defined subtypes separated the patients in their survival time, age of first diagnosis and
tumor nucleic percentages much better.
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Table 7: P-value of the dependence test for different clinical features and GBM
subtypes
Method Survival Age
Tumor necrosis
percentage
Tumor nuclei
percentage
NCIS 0.0241** 0.0608* 1.14× 10−4*** 3.26× 10−3***
NCIS (α = 0) 0.0140** 0.0278** 3.29× 10−4*** 4.28× 10−3***
NCIS (W = I) 0.0321** 0.0402** 1.70× 10−3*** 2.37× 10−3***
Consensus clus-
tering (k = 4)
0.101 0.124 1.09× 10−4*** 0.0105**
GBM paper
(Verhaak et al.,
2010)
0.153 0.0135** 3.25× 10−5*** 8.80× 10−3***
For survival time, we used logrank test; for tumor necrosis percentage, tumor nuclei
percentage and age at initial pathologic diagnosis, we used ANOVA. * for p < 0.1, **
for p < 0.05, *** for p < 0.01.
We trained a classifier based on the first 30 genes (shown in Figure 5) with highest
weights and largest expression differences between subtypes. Like what we did in BRCA
data analysis, we also used different numbers of genes to train classifier and got accuracy
estimations based on the average accuracy of 10-fold cross validation for 20 times. We
selected a smallest number of genes which can give accuracy higher than 0.90 (Figure 7).
After evaluating the accuracy with 10-fold cross validation, we trained a classifier using all
the 202 samples (30 genes), and then used this classifier to predict the subtypes of these
202 sample in turn. The accuracy we got is 0.960.
We tested the functions of the 30 genes used in the classifier. According to DAVID
(Huang da et al., 2009a,b), they are enriched in pathways related to immune response,
endocytosis, apoptotic process, etc. (Table 8). These functions were reported to play im-
portant roles in cancer progression. For example, derailed endocytosis of surface receptors
can abnormally regulate crucial features of signal transduction (Hanahan and Weinberg,
2000; Mosesson et al., 2008); loss of apoptosis can disrupt the balance between cell prolif-
eration and cell death and lead to cancer (Fesik, 2005).
We also extracted a subnetwork to illustrate the difference between subtypes in network
level. Here we considered gene C1QA (Figure 8), which is involved in immune response
(GeneCards, (Safran et al., 2010)). We selected this subnetwork because it has a compact
structure. As can be seen from Figure 8, downstream targets like C1QB and C2 have
very similar expression pattern with C1QA. However, cases are more complicated for genes
like IGKV1-5 and IGKC. We think this is due to the large number of upstream genes for
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Figure 6: Kaplan-Meier survival curves of GBM data. Red for Subgroup Neural,
green for Mesenchymal, blue for Proneural and purple for Classical; horizontal axis is the
survival time (days) and vertical axis is the survival rate). a. NCIS-defined subtypes; b.
NCIS (α = 0) defined subtypes; c. NCIS (W = I) defined subtypes; d. Consensus clustering
(k = 4) defined subtypes; e. GBM paper defined subtypes.
IGKV1-5 and IGKC: they also exert an influence on IGKV1-5’s and IGKC’s expression.
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Figure 7: Accuracies of GBM subtype classifiers trained with different numbers
of genes. Genes with largest weights and largest expression differences were used.
Table 8: Pathways enriched by GBM 30 genes
Term P-value
Chemokine signaling pathway 2.76× 10−6
Leukocyte transendothelial migration 3.71× 10−5
Regulation of actin cytoskeleton 2.19× 10−4
Cytokine-cytokine receptor interaction 3.42× 10−4
Fc gamma R-mediated phagocytosis 1.27× 10−3
Natural killer cell mediated cytotoxicity 2.08× 10−3
Endocytosis 3.62× 10−3
Glioma 0.0364
B cell receptor signaling pathway 0.0427
Chronic myeloid leukemia 0.0452
Hematopoietic cell lineage 0.0489
TGF-beta signaling pathway 0.0495
Apoptosis 0.0495
p-value<0.05, results from DAVID.
3.3 Simulated Datasets
To better evaluate the accuracy of NCIS, we simulated a set of expression profiles composed
of 300 samples and 3 subgroups. The gene expression values were generated according to
the real expression profile in the BRCA dataset (Network, 2012).
We assume for sample i in subgroup k, gene expression x·i ∼ N (µk, Σ), where µk is
a column vector representing the mean expression levels for subgroup k, and Σ is used to
model the network structure and the variance within subtype. To estimate Σ, we used
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Figure 8: Expression patterns of C1QA subnetwork in GBM subtypes. Genes
directly connected to C1QA and genes targeting C1QA’s downstream genes are included.
Color of circle corresponds to gene expression level; size of circle corresponds to gene weight.
a. Subtype Neural; b. Subtype Mesenchymal; c. Subtype Proneural; d. Subtype Classical.
graph Laplacian of the network. We first obtained an adjacency matrix A˜ from the original
network matrix E : A˜ = max(E, E′), where E′ is the transposal of E. The degree matrix
D˜ is defined as a diagonal matrix with entries equal to the sum of the corresponding rows
of A˜. The graph Laplacian is thus L = D˜ − A˜. We estimated Σ as:
Σ = ν(I − D˜− 12 A˜D˜− 12 ). (3.1)
The main idea is that expression levels of genes connected in the network structure
would be correlated. Here we assume the correlations are proportional to the proximities
in the network. We use this technique to simulate datasets so interactions between genes
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can be considered. To determine constant ν, we compared the diagonal entries of matrix
I− D˜− 12 A˜D˜− 12 (expression variances) and the variances of real gene expression levels in the
BRCA dataset. In our simulation, we set ν = 0.5.
For the three subtypes we simulated here, the mean expression levels of each gene were
estimated from the gene expression profiles of Luminal A, Basal and Luminal B detected in
the BRCA dataset. The final simulated datasets contain 300 samples and 8,726 genes.
Some noises were added to the datasets, otherwise the signal would be too strong. We
first trained a weight for each gene based on only the network structure (α = 1 in the weight-
training algorithm) and then chose l genes with lowest weights to be “noninformative” genes:
we randomly permutated the expression levels of these genes across the samples. l was set
to be 1,000, 2,000, 3,000, 4,000 and 5,000 to illustrate the influence of noises. We generated
5 datasets for each l.
We set m = 8 and c = 3 in NCIS. The results for multiple trials of the simulation studies
were shown in the Table 9. We also included the results for consensus clustering here. As
we can see, when the number of “noisy” genes is small (1000 and 2000), both methods have
100% accuracy; when there are 3000 noises, NCIS begins to perform better than consensus
clustering. However, if there are too many noises (5000), neither method can have very
good prediction. Considering that the total number of genes used here is less than 9000,
this poor performance is acceptable. Overall, our simulation studies indicate that NCIS is
a robust method that can detect cancer subtypes very accurately.
Table 9: Clustering accuracies on simulated datasets
#“noisy” Case 1 Case 2 Case 3 Case 4 Case 5
genes NCIS Cons NCIS Cons NCIS Cons NCIS Cons NCIS Cons
1000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
2000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
3000 1.000 0.913 0.997 0.887 0.907 0.897 1.000 0.877 1.000 0.870
4000 1.000 0.797 0.720 0.673 0.807 0.727 1.000 0.680 0.703 0.703
5000 0.710 0.633 0.573 0.573 0.680 0.547 0.613 0.613 0.677 0.567
For each given number of “noisy” genes, we simulated 5 datasets (Case 1-5).
“Cons” for consensus clustering.
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Chapter 4
Conclusion
Cancer subtype information is of critical importance in designing better treatment strategy.
In this work, we aim at developing a clustering method that can help identify cancer subtypes
from high-throughput gene expression data and select subtype-related gene sets. We propose
a new co-clustering method that incorporates the network information within the clustering
step to detect biologically informative sample subtypes and co-expressed gene sets. The
main rationale underlying our method is as follows. First, genes playing key roles in network
should be more emphasized than down-stream target genes; therefore we assign a weight to
each gene based on its connectivity in network and the distinguishing ability in expression
level across all samples. This weight also serves as a natural feature selection criterion
since key genes will be more favored in the clustering algorithm. We also avoid excluding a
large number of genes using this kind of feature selection. Less information loss should be
beneficial for subsequent analysis. Second, a co-clustering method can better capture the
duality of gene expression profiles, in terms that similarity is treated as a level of coherence
of the samples and genes in the bi-clusters; thus we construct the model based on a co-
clustering method, SNMTF, considering its intuitive meaning and its ability to handle gene
expression dataset. We search for the minimum of the objective through iterative algorithms.
Since our method takes prior knowledge on network structure to guide the clustering, we
expect that the clustering results would be more biologically relevant and more resistant
to the spurious similarities, compared to subtypes clustering methods only based on the
expression matrix. We tested our method on two large-scale expression profiles and several
simulated datasets. We were able to detect distinct subtypes that are biologically meaningful
in both real datasets and to cluster most samples correctly in the simulated ones. These
results suggested that our method provides a unique solution to cancer subtype identification
based on gene expression profiles.
There are several future directions. First, the network we used is assumed to be a generic
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molecular interaction network, i.e., it is not specific for the particular type of cancer or the
tissue used in the experiment. Second, the network does not contain all the genes, so some
genes were excluded simply because we cannot assign a comparable weight for it. Third,
a lot of edges in our current network do not have high confidence level and the directions
of many edges are unclear. These three problems are mainly due to a lack of complete
pictures on gene-gene interaction mechanisms, especially cancer-specific or tissue-specific
network information. A possible approach dealing with the first two network problems is
to update the network information according to the expression patterns. The “posterior”
network generated could be more specific and guide the clustering better. Besides, with
more knowledge accumulated on gene network, we believe the performance of our method
can be further improved. In addition, we think the gene weights trained from NCIS could be
applied to the consensus clustering for feature resampling. Consensus clustering outperforms
many conventional methods since it integrates the results across multiple runs of a regular
clustering on subsets of samples. However, our result indicated that its robustness decreased
as the dimension became large. Therefore, a proper weight input for resampling the features
may help in selecting more informative genes. This modified version of consensus clustering
can also be integrated with co-clustering frameworks.
Overall, we believe our new NCIS method will be highly useful to comprehensively
identify subtypes that are otherwise obscured by cancer heterogeneity, from various types
of cancers based on high-throughput and high-dimensional gene expression data.
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